Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. April 2026 07:00 ET | Quelle: X4 Pharmaceuticals

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April ...
13. April 2026 08:00 ET | Quelle: Veld Pharmaceuticals GmBH

Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa

Veld Pharmaceuticals, announced a collaboration with Chiesi Farmaceutici S.p.A in Africa for Rare Disease Therapies
09. März 2026 18:30 ET | Quelle: Custom Market Insights

[Latest] Global Intravenous Infusion Pump Market Size/Share Worth USD 14.02 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, March 10, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Intravenous Infusion Pump Market Size, Trends and Insights By Product Type...
02. März 2026 16:30 ET | Quelle: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on...
08. Januar 2026 07:00 ET | Quelle: Aronora

Aronora Appoints Industry Leaders to Drive Next Phase of Growth

Grace E. Colón, Ph.D., Appointed Chair of the Board of Directors John Glasspool Appointed Board Director Lekhan Shivashankar Appointed Chief of Staff New Additions Strengthen Aronora as it Advances...
09. Dezember 2025 07:30 ET | Quelle: Novartis Pharma AG

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with...
06. Dezember 2025 08:30 ET | Quelle: Adaptive Biotechnologies

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive announces deep interventional use of clonoSEQ across abstracts at ASH
04. Dezember 2025 08:59 ET | Quelle: Parexel International LLC

Parexel Showcases Industry-Leading Hematology Expertise with Presentation of 10 Research Posters at the American Society of Hematology (ASH) Annual Meeting

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life...
02. Dezember 2025 12:13 ET | Quelle: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
24. November 2025 07:30 ET | Quelle: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Adaptive's clonoSEQ MRD Testing in Clinic and Research Settings Across ~90 Abstracts

Nächste Seite